Ekta Batra

Mumbai

Anchor and Associate Editor Research at CNBC-TV18

Editor, Pharmaceutical and Health, CNBC TV18. Reporting, Analysing Pharma & Health since 2008. Tweets personal. Coffee & puppy addict. Myopic bt not in my views

Featured in: Favicon

cnbctv18.com Favicon

msn.com

moneycontrol.com Favicon

flipboard.com Favicon

topologypro.one

Articles

Lupin's new drug launch could contribute over 25% of its FY26 earnings, analyst says

3 weeks ago | topologypro.one | Ekta Batra

Shares of Lupin Ltd shares gained nearly 4% on Tuesday, May 13, as the pharma company launched the Tolvaptan tablets or Jynarque generic in the US market. Axis Capital said Lupin is expected to be the only generic player for the most of the financial year 2026. The company's revenue opportunity for the ongoing fiscal is estimated at $150 million to $200 million.
Piramal Pharma shares likely to react to multiple triggers on Tuesday

3 weeks ago | topologypro.one | Ekta Batra

Piramal Pharma Ltd. shares are in focus on Tuesday, May 13, after the company on Monday said it is investing $90 million for the expansion of its Lexington and Riverview facilities in the US. The company said the expansion is aligned with the growing US customer demand and onshoring of drug supply. The Lexington facility will add 24,000 square feet of sterile injectable manufacturing space, etc. It is expected to be completed by late 2027.
High levels of toxic flame retardants in black plastic kitchen utensils: Study

Oct 2, 2024 | cnbctv18.com | Ekta Batra

A recent research highlighted serious health concerns regarding black-coloured plastic kitchen utensils, which may contain alarming levels of toxic flame retardants.
Serum Institute of India flags off first consignment of R21/Matrix-M Malaria vaccine to Africa

May 20, 2024 | cnbctv18.com | Ekta Batra

Vaccine manufacturer Serum Institute of India has begun exports of the 'R21/Matrix-M' malaria vaccine to Africa. The vaccine is developed in collaboration with the University of Oxford and Novavax’s Matrix-M adjuvant.
Biocon Group CEO sees enormous opportunities in weight loss drugs market

May 17, 2024 | cnbctv18.com | Ekta Batra

Peter Bains, Group CEO of Biocon, discussed the past quarter, future debt reduction plans, and the extensive pipeline of diabetes and weight management drugs, including Liraglutide, Semaglutide, and Tirzepatide, in an interview with CNBC-TV18."The scale of the market opportunity is enormous.
Kalyani Steels working to fully pass on input cost increases soon

May 15, 2024 | cnbctv18.com | Ekta Batra

RK Goyal, Managing Director of Kalyani Steels, expects the earnings before interest, taxes, depreciation, and amortisation (EBITDA) margin to expand to more than 20% over the next couple of years as utilisation at its new capacities increases .Currently, the margin is under pressure because the company has been unable to reach an agreement with original equipment manufacturers (OEMs) to fully pass on the intended cost increases.A: The growth is largely related to increase in volume.
Benefits of Semaglutide as per study published in Nature Medicine

May 13, 2024 | cnbctv18.com | Ekta Batra

A recent study featured in the medical journal Nature Medicine has indicated that semaglutide, a medication used for treating diabetes and aiding weight loss, can reduce the likelihood of major heart issues by 20%.Semaglutide, administered weekly via injection, belongs to the GLP-1 group of drugs, primarily prescribed for adults with Type 2 diabetes but also approved for weight management.
Piramal Pharma aims to grow innovation business faster than generics

May 12, 2024 | cnbctv18.com | Ekta Batra

Parimal pharma surged in trade today on the back of strong January-March earnings. Revenue for the quarter grew 18% over last year towhile profit doubled toargin, at 20.8%, was at a multi quarter high. In the third quarter, margin was at 13.7%.Nandini Piramal, Chairperson of company discussed the innovation spending in FY25, and the biotech scenario in the US with CNBC-TV18.“We've seen that our innovation related business for the first time last year, in FY24, crossed 50%.
Jupiter Life Line Hospitals to set up new 500-bed hospital in Pune this year

May 12, 2024 | cnbctv18.com | Ekta Batra

Jupiter Life Line Hospitals plans to build a 500-bed hospital in Pune during April-March 2024-25.Given the strong demand in Pune, there's an opportunity to incorporate 22 new suite rooms, said Chief Executive Officer, Ankit Thakker.Jupiter reported a revenue of ₹290 crore in January-March versus ₹242 crore in the same quarter last year. Profit grew to ₹45 crore from ₹16 crore.A: The occupancy for this year has been about 64% on a blended level.
Suryoday SFB expects 30-35% asset growth, 40% growth in deposits in FY25

May 9, 2024 | cnbctv18.com | Ekta Batra

Suryoday Small Finance Bank (SFB) is expecting its assets to grow at least 30% in the financial year 2025, and it is also confident about a 40% growth in deposits in the same year.In an exclusive interview with CNBC-TV18, SFB Managing Director & CEO Baskar Babu Ramachandran said that he is confident of the bank's performance, anticipating a substantial asset growth of 30-35% alongside 40% increase in deposits for the upcoming financial year.However, Ramachandran also mentioned a slight...